NeuroDerm Parkinson’s Drug Inches Closer To Market With Phase III Win
Mitsubishi Tanabe Pharma paid $1.1bn to acquire the Israeli biotech in 2017 for a drug that analysts forecast to represent a market opportunity worth up to $1.7bn in peak sales.
You may also be interested in...
The major will use the biotech’s brain cell-focused platform technology to discover new targets for Alzheimer’s disease.
Novartis and Roche may be committed to the target, but AbbVie has decided that its efforts in Parkinson's will not include a Phase II trial of its Swedish partner's alpha synuclein drug.
Promising results from a small Phase II study will now propel the company’s CVN424 into pivotal trials, though its optimum dose is still unclear.